key: cord-0870459-gxjfojxl
authors: Lao, Nicole; Lim, Joseph; Mahalwar, Gauranga; Adebolu, Olayinka; Mangira, Caroline; Courson, Jeffrey; Hegde, Vinayak
title: Incidence of Atrioventricular Blocks and its Association with In-Hospital Mortality and Morbidity in Patients with Coronavirus Disease 2019
date: 2021-11-01
journal: J Cardiol
DOI: 10.1016/j.jjcc.2021.10.025
sha: bb5cffa182285ce4d4f50ee6b0113e27a9a8661f
doc_id: 870459
cord_uid: gxjfojxl

BACKGROUND: Cardiovascular sequelae of coronavirus disease 2019 (COVID-19) infection have been explored by clinicians and researchers all over the world. OBJECTIVE: The purpose of this study was to evaluate the incidence of atrioventricular block (AV) in patients hospitalized for COVID-19 and its association between in-hospital morbidity and mortality. METHODS: In-hospital electrocardiograms (ECGs) of 438 patients were compared with their prior or baseline ECGs to ascertain the development of new onset AV block. Patients who developed new AV blocks were then followed at 30 and 90 days post-discharge to check for resolution of AV block. Demographic characteristics, clinical characteristics, and complications during their hospital stay were evaluated. Major complications including respiratory failure requiring oxygen supplementation and mechanical ventilation, sepsis, deep vein thrombosis, elevated troponins, hospital and intensive care unit (ICU) length of stay, as well as death were compared between those who developed new onset AV blocks and those who did not. RESULTS: Based on our single center study, the incidence of new onset AV blocks among patients admitted for COVID-19 during the study period was 5.5 cases per 100 patients. New onset AV blocks were not associated with longer hospital and ICU length of stay, increased intubation rates, or increased mortality. CONCLUSION: Although the development of a new onset AV block is most likely multifactorial and not solely due to COVID-19, it is still important for clinicians to be mindful about the possibility of developing symptomatic bradycardia and life-threatening arrhythmias in patients admitted for COVID-19. This can be achieved by appropriate rhythm monitoring in-patient but the need for a cardiac event monitor upon discharge is unlikely to be necessary. Careful history taking, including family and drug use history is also of great importance as emerging drug therapies for COVID-19 have potential arrhythmogenic effects.

Nicole Lao (MD) a , Joseph Lim (MD)

Since the first case of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2 virus) was reported at the end of 2019, coronavirus disease 2019 (COVID- 19) has become a serious threat to global public health. Although the disease mainly affects the respiratory system, its effects on the cardiovascular system are increasingly being recognized [1, 2] . While myocardial damage, as shown by increased high sensitivity troponin and fulminant myocarditis, has been reported, cardiovascular complications such as malignant arrhythmias are still largely unknown. In one study of 138 hospitalized patients with COVID-19, arrhythmia (not further specified) was reported in 17% of total patients and in 16 of 36 patients admitted to the intensive care unit (ICU) [1] . Therefore, an arrhythmogenic effect of COVID-19 could be expected, potentially contributing to disease outcome. With growing data in the literature reporting the incidence of arrhythmias in COVID-19 patients, the incidence of atrioventricular (AV) blocks has not been well reported.

Bradycardias due to either sinus node disease or AV blocks are an important cause of age-related cardiovascular morbidity [3] . Presentation is typically with symptoms of dizziness, syncope, or effort intolerance and either an abnormal resting electrocardiogram (ECG) or rhythm monitoring can help to establish the diagnosis. While first degree AV blocks are benign and do not show an interruption of the AV conduction, second and third-degree AV blocks are considered life-threatening as they translate to interruption of AV conduction, and even complete dissociation of the atrial and ventricular conduction, requiring emergent permanent pacemaker placement (PPM).

While PPM implantation for all degrees of heart block may have symptomatic benefit, implantation in the context of Mobitz II, other higher degree AV blocks and third-degree heart block, has proven survival benefit [3] .

Acknowledging the lack of data concerning these AV blocks in patients admitted for COVID-19, the objective of this study was to evaluate the incidence of AV blocks and its effect on disposition and in-hospital outcomes among patients with COVID-19.

This retrospective study was approved by the local institutional review board with a waiver of informed consent because of the minimal risk to participants. 

Descriptive statistics, as well as inferential statistics were performed, as appropriate. Categorical variables were described using frequencies and percentages, and p-values obtained using chi square tests or Fisher's exact tests, as applicable. Continuous variables were described using medians and interquartile range, or mean and SD according to their distribution and p-values obtained from t-tests or Wilcoxon rank sum tests. Dispositions and in-hospital complications were compared between those who developed new onset heart blocks and those who did not. ICU length of stay and hospital length of stay were also compared between the two groups. Due to the small number of patients who developed new onset heart blocks during the study period, multiple logistic regression analysis was not performed. Analyses were performed using SAS® Software (version 9.4; Cary, NC, USA). A significance level of 0.05 was assumed.

Among the study population, 110 ten subjects (55%) were female, and the median age was 68 years old with a standard deviation of ±16.15 years. One hundred twenty-three (62%) were

Caucasian, 67 (34%) were African American, and 6 (3%) were either Asian or Hispanic.

Patients who were admitted with COVID-19 were predominantly blood group A. Sixty-four percent of the patients had a normal sinus rhythm prior to admission, while 10% of the patients had atrial fibrillation prior to admission. At admission, normal sinus rhythm was observed in 46.5% of these patients, atrial fibrillation was observed in 8.5% of patients. Rhythms, such as atrial flutter (2%), atrial tachycardia and junctional rhythm were much less common (<1%). The most common comorbidity among admitted patients was hypertension n=139 (69.5%), followed by diabetes n=75 (37.5%), coronary artery disease n=46 (23%), obesity n=41 (21%), and heart failure n=37 (18.5%). Of the patients included in the study, 17 (8.5%) had a known history of hypothyroidism all of which were controlled on presentation with no therapeutic intervention (see Table 1 ).

Of the 200 patients included, 11 (5.5%) patients were confirmed to have ECG changes consistent with a new onset AV block. The incidence of AV blocks among COVID-19 patients was reported to be 5.5 cases per 100 patients. Nine patients were reported to have first-degree AV block. One patient was reported to be with a high-degree AV block requiring pacemaker placement. The patient was a 71-year-old Caucasian male who initially presented with fatigue and generalized weakness at an outside facility. He did not require oxygen supplementation. He subsequently developed a high-degree AV block with ventricular response in the 20s. He was started on dexamethasone and remdesivir while at the outside facility, which was discontinued immediately after the occurrence of the heart block. Another patient had a transient second-degree Mobitz Type 2 AV block. The patient was a 70-year-old African American female with vascular dementia who was asymptomatic and was previously on metoprolol succinate which was continued during admission. Prior to discharge, she spontaneously converted to sinus rhythm and did not require a permanent pacemaker placement. She received dexamethasone therapy only.

She was discharged with a 30-day event recorder and was found to have recurrence of her second-degree Mobitz Type 2 AV block. A dual chamber pacemaker was then placed.

Two patients remained in first-degree AV block at 90-day follow-up and no intervention was made. One patient showed resolution of the first-degree AV block after percutaneous coronary intervention (PCI). Out of the remaining 6 patients, 3 expired during hospital admission and 3

were lost to follow-up (see Tables 2 and 3 )

Among patients admitted with COVID-19, ninety-one developed respiratory failure requiring oxygen supplementation in the form of regular and hi-flow nasal cannula, noninvasive positive pressure ventilation (see Table 4 ). In this same subset of patients, 29 required mechanical ventilation and subsequent admission to the ICU. New onset heart block was seen in six (6.5%) of these patients who developed respiratory failure. Troponin elevation was observed in seven of the patients. Out of these seven patients, only one had a new onset heart block in the setting of anterior myocardial infarction. The same patient underwent PCI which revealed a 90% occlusion in the proximal left anterior descending artery. The six other cases of NSTEMI were from demand supply mismatch (Type 2) (see Table 5 ). Acute kidney injury was observed in 33 patients and 2 (6%) of the 33 had a new onset heart block. No incidence of new onset AV block was found in the other complications including sepsis, anemia requiring transfusion, deep vein thrombosis, pulmonary embolism, and stroke (see Table 5 ).

There was no difference in in-hospital mortality among patients who developed AV blocks compared with patients who did not [2 (18.18) Table 6 ).

Cardiovascular morbidity in patients with COVID-19 has been reported to include the following: myocardial injury, takotsubo cardiomyopathy, atrial arrhythmias, acute myocarditis, and even pulseless electrical activity arrest [4, 5, 6, 7, 8, 10, 11] . Lau et al. demonstrated that sinus tachycardia was the most common cardiovascular SARS-CoV finding, with an overall incidence of 72%; and significant sinus bradycardia was seen in 18 (14.9%) patients. Unlike tachycardia which manifests to be persistent, bradycardia was somewhat transient [12] .

There have been a few reports regarding the incidence of cardiac arrhythmias in COVID-19, but whether or not the virus specifically affects the conduction system of the heart, is still largely unknown. Additionally, the effects of new onset AV blocks in terms of patient outcomes remain unclear.

Our study showed that arrhythmias, particularly new onset AV blocks can occur in COVID-19

patients. Several mechanisms have been proposed regarding the pathophysiology of arrhythmias in this subset of patients [13] [14] [15] . Given that angiotensin-converting enzyme 2, the entry receptor for the causative coronavirus SARS-CoV-2, is expressed in multiple extrapulmonary tissues, including the cardiomyocytes, direct viral tissue damage causing electrical system conduction is a plausible mechanism of injury [13] . It is unclear whether inflammation, and resulting edema play a role in the development of transient AV blocks, and whether healing with fibrosis ultimately leads to permanent conduction system damage. Effects of the virus on ion channels have not been studied to our knowledge.

One postulated theory is that the infection in the pericardium causes massive edema and ischemia. Myocardial fibrosis from the recent viral infection can predispose patients to arrhythmias [14] , particularly ventricular tachycardias. Elevation in cardiac and inflammatory markers may reflect a direct effect of the virus on the cardiac conduction system. Lastly, proinflammatory cytokines can also predispose these patients to arrhythmogenicity [14] . Other theories postulate worsening/further deterioration of preexisting cardiovascular debility in the setting of a viral infection, due to increasing metabolic demand in the setting of reduced cardiac reserve. This imbalance, along with an accentuated inflammatory response and myocardial damage, could raise the risk of acute coronary syndromes, heart failure, and arrhythmias [5] . Preexisting conduction system disease or infiltrative disease are unlikely to be the underlying cause for the patients who were found to have first-degree AV blocks, as most of the patients did not have known infiltrative disease or conduction system disease, and had normal ECG findings prior to admission.

Patients who were admitted with COVID-19 infection were predominantly blood group A. This is consistent with an associated reported for SARS-COV-1, in which O blood groups were less common among SARS patients [17] . Our findings are also consistent with the results reported by Zhao et al. [18] where non-O types appear to be at a greater risk of infection and the metaanalysis performed by Pourali et al. [19] which showed that individuals with blood group A are at higher risk for COVID-19 infection while those with blood group O are at a lower risk.

This study also showed that there was no significant difference in morbidity and mortality in patients who developed new onset AV blocks compared to those who did not. Specifically, new onset AV blocks were not associated with longer hospital and ICU length of stay, increased intubation rates, or increased mortality. Our results are in line with prior reports that have illustrated that the various cardiac arrhythmias associated with COVID-19 infection do not necessarily correlate with the extent of the lung injury of these patients [9, 10] . However, the results of this study were contrary to those of a small cross-sectional cohort study by Shi et al., where they reported higher mortality and intubation rates in patients with COVID-19 who developed concomitant conduction abnormalities [16] . This study was reported among 416 hospitalized patients in a single center in Wuhan, China.

Although the results of this study showed that most of the new onset AV blocks identified were clinically benign and did not result in an increase in overall mortality, it is notable to mention that one patient developed a high-grade AV block that required pacemaker placement. This patient had no pre-existing electrophysiologic issues to our knowledge. This finding is similar to previously reported rare cases about younger patients, with no underlying medical, cardiac, or drug history, who developed high-grade AV blocks while being hospitalized for COVID-19 [3, 4] . Although the development of a new onset AV block is most likely multifactorial and not solely due to COVID-19, it is still important for clinicians to be mindful about the possibility of developing symptomatic bradycardia and life-threatening arrhythmias in patients admitted for COVID-19. This can be achieved by appropriate rhythm monitoring in-patient but the need for a cardiac event monitor upon discharge is unlikely to be necessary. Careful history taking, including family and drug use history is also of great importance as emerging drug therapies for COVID-19 have potential arrhythmogenic effects [17] .

The results of this study also suggest that viral injury arrhythmias, specifically, AV blocks, sinus bradycardia, and atrial fibrillation, are likely the consequence of systemic illness and not solely the direct effects of COVID-19 infection. Many of the patients who developed AV blocks had underlying comorbidities and cerebrovascular diseases, such as hypertension, coronary artery disease, heart failure, prior stenting or bypass surgery, obstructive sleep apnea, and obesity.

While this study assessed the occurrence of new onset AV blocks and their association with morbidity and mortality, there were limitations. The sample size in this study is relatively small and a larger sample size from multiple centers may confer a much better estimation of the true relationship between COVID-19 and arrhythmias. There is also no control group (those without COVID-19) used to compare the incidence of new onset AV blocks. Another limitation would be that baseline medications as well as preexisting bundle branch block conferring risks to development of high-grade AV block were not factored into the study. Next, for patients who developed AV blocks, an underlying conduction system disease could not be entirely excluded as some patients were lost to follow-up after discharge and did not undergo an electrophysiology study. Moreover, this study design did not take into account the use of hydroxychloroquine and azithromycin in these patients. The investigators also did not look into QT prolongation in patients who were admitted for COVID-19 and in patients who developed heart blocks. Another limitation of the study is that the authors focused on AV blocks and did not take into account sick sinus syndrome (SSS) as the cause of bradycardias in these patients. Further studies are needed which will take into account SSS and AV blocks as a cause of bradyarrythmias, in patients with COVID-19.

COVID-19 is known to be associated with not only respiratory, but also cardiac injury. The AV, atrioventricular; ECG, electrocardiogram. 

SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Heart Rhythm

Characteristic Electrocardiographic Manifestations in Patients With COVID-19

Evidence for reduced susceptibility to cardiac bradycardias in South Asians compared with Caucasians

Transient complete heart block in a patient with critical COVID-19

HEART BRAKE-An unusual cardiac manifestation of coronavirus disease 2019 (COVID-19)

Cardiac and arrhythmic complications in patients with COVID-19

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA

Guidance on Short-Term Management of Atrial Fibrillation in Coronavirus Disease

Behavior of the PR interval with increasing heart rate in patients with COVID-19

Cardiac Arrhythmias in COVID-19 Infection

Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic

Tachycardia amongst subjects recovering from severe acute respiratory syndrome (SARS)

Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management

The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2

Arrhythmias in myocarditis: State of the art

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology

ABO blood group and susceptibility to severe acute respiratory syndrome

Relationship Between the ABO Blood Group and the Coronavirus Disease 2019 (COVID-19) Susceptibility

Relationship between blood group and risk of infection and death in COVID-19: a live meta-analysis